Novavax (NASDAQ:NVAX) announces that
it intends to launch a Phase 1 clinical trial in the coming weeks at
its Melbourne and Brisbane clinics for NVX-CoV2373, its SARS-CoV-2
Recombinant Spike Protein Nanoparticle vaccine. The study should start
in mid-May with initial data available in July.
Shares up 3% premarket on light volume.
https://seekingalpha.com/news/3561170-novavax-set-to-launch-clinical-development-of-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.